Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

71.63  -5.73 (-7.41%)

After market: 70.57 -1.06 (-1.48%)

Fundamental Rating

2

Overall SLNO gets a fundamental rating of 2 out of 10. We evaluated SLNO against 551 industry peers in the Biotechnology industry. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.
In the past year SLNO has reported a negative cash flow from operations.
In the past 5 years SLNO always reported negative net income.
SLNO had a negative operating cash flow in each of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of SLNO (-54.49%) is comparable to the rest of the industry.
SLNO has a Return On Equity (-75.41%) which is in line with its industry peers.
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

SLNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SLNO has been increased compared to 5 years ago.
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 21.34. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
SLNO has a better Altman-Z score (21.34) than 93.48% of its industry peers.
SLNO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, SLNO is doing worse than 69.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 21.34
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 15.13 indicates that SLNO has no problem at all paying its short term obligations.
SLNO has a Current ratio of 15.13. This is amongst the best in the industry. SLNO outperforms 89.31% of its industry peers.
A Quick Ratio of 15.01 indicates that SLNO has no problem at all paying its short term obligations.
SLNO's Quick ratio of 15.01 is amongst the best of the industry. SLNO outperforms 89.31% of its industry peers.
Industry RankSector Rank
Current Ratio 15.13
Quick Ratio 15.01
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SLNO have decreased strongly by -69.67% in the last year.
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 48.30% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.79%
EPS Next 2Y51.35%
EPS Next 3Y48.3%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 57.86, SLNO can be considered very expensive at the moment.
89.31% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
SLNO is valuated expensively when we compare the Price/Forward Earnings ratio to 35.34, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 57.86
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SLNO does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 48.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.35%
EPS Next 3Y48.3%

More info and screens

0

5. Dividend

5.1 Amount

SLNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (8/15/2025, 8:00:02 PM)

After market: 70.57 -1.06 (-1.48%)

71.63

-5.73 (-7.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners105.59%
Inst Owner Change2.62%
Ins Owners1.45%
Ins Owner Change-13.48%
Market Cap3.72B
Analysts86.67
Price Target116.85 (63.13%)
Short Float %12%
Short Ratio5.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.18%
Min EPS beat(2)-0.42%
Max EPS beat(2)80.77%
EPS beat(4)1
Avg EPS beat(4)-28.52%
Min EPS beat(4)-186.49%
Max EPS beat(4)80.77%
EPS beat(8)2
Avg EPS beat(8)-30.55%
EPS beat(12)5
Avg EPS beat(12)-17.7%
EPS beat(16)8
Avg EPS beat(16)-9.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.4%
PT rev (3m)8.53%
EPS NQ rev (1m)75.65%
EPS NQ rev (3m)66.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.92%
Revenue NQ rev (1m)164.65%
Revenue NQ rev (3m)383.86%
Revenue NY rev (1m)125.93%
Revenue NY rev (3m)144.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 57.86
P/S 113.77
P/FCF N/A
P/OCF N/A
P/B 15.47
P/tB 15.86
EV/EBITDA N/A
EPS(TTM)-4.14
EYN/A
EPS(NY)1.24
Fwd EY1.73%
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0.63
BVpS4.63
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.53%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.13
Quick Ratio 15.01
Altman-Z 21.34
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
EPS Next Y24.79%
EPS Next 2Y51.35%
EPS Next 3Y48.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-165.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-282.33%
OCF growth 3YN/A
OCF growth 5YN/A